Quetiapine placebo-controlled studies

Atmaca M, Kuloglu M, Tezcan E, Gecici O (2002) Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder a single-blind, placebo-controlled study. Int Clin Psychopharmacol 17 115-119... 

In the Expert Consensus survey, the respondents endorsed risperidone, olanzapine, and quetiapine, in that order, followed by high-potency traditional antipsychotics, for managing self-injury. A placebo-controlled study comparing risperidone with a classical antipsychotic, such as haloperidol, could provide valuable data for this field. 

A systematic review of quetiapine included 12 studies [69]. The attrition rate in the four placebo-controlled studies was almost as high as in the olanzapine studies (quetiapine -53%, placebo -60%), the RR being 0.84 (Cl 0.7-0.9 NNT 11 Cl 7-55) thus, it is rather difficult to interpret the data with such Cl-values. [RR = relative risk in randomized controlled trials, the ratio of rate of negative events in the exposed group to the rate in controls.]... 

Sachs G, Chengappa KNR, Suppes T, Mullen JA, Brecher M, Devine NA, Sweitzer DE. Quetiapine with lithium or divalproex for the treatment of bipolar mania a randomized, double-bhnd, placebo-controlled study. Bipolar Disord 2004 6 213-23. 

In a double-blind, randomized, placebo-controlled study quetiapine was associated with significant cognitive decline in 93 patients with Alzheimer s disease, dementia, and clinically significant agitation (592). 

Nasrallah HA, Brecher M, Paulsson B, Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania. Bipolar Disord 2006 8(5 Pt l) 467-74,... 

A randomised, placebo-controlled study in 191 patients found that quetiapine, combined with either lithium or valproate semisodium (divalproex sodium), was superior to lithium or valproate semisodium alone for treating bipolar mania. The incidence of extrapyramidal symptoms in patients receiving quetiapine with lithium or valproate semisodium was similar to those receiving placebo with lithium or valproate semisodium. No special precautions would therefore appear to be necessary on concurrent use. 

Placebo-controlled studies Paliperidone modified-release, quetiapine, and placebo have been compared in patients with recently exacerbated schizophrenia requiring hospitalization in a 6-week double-blind study [102 ]. In-patients were randomly assigned to paliperidone modified-release (n = 160), quetiapine (n = 159), or placebo (n = 80). A 2-week monotherapy phase was followed by a 4-week additive-therapy phase target doses were at the... 

Honer WG, MacEwan GW, Gendron A, Stip E, LabeUe A, Williams R, et al. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin PsycWatry 2012 73(l) 13-20. 

Calabrese JR, Bowden CL, Sachs GS, et al A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Lamictal 605 Study Group. J Clin Psychiatry 64 1013-1024, 2003 Calabrese JR, Keck PE, Macfadden W, et al A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar 1 or 11 depression. Am J Psychiatry 162 1351-1360, 2005 Chen G, Manji HK, Hawver DB, et al Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 63 2361-2364, 1994... 

Arvanitis and Miller (129) reported a multiple fixed-dose, placebo-controlled, double-blind study of quetiapine in comparison with haloperidol and placebo in acutely exacerbated patients with chronic schizophrenia. Quetiapine was administered in five doses 75, 150, 300, 600, and 750 mg/day haloperidol was given at 12 mg/day. The study design had slightly more than 50 patients in each group. The 75-mg dose of quetiapine was clearly less efficacious than the higher doses. Doses of 150 to 750 mg/day were superior to placebo and comparable with haloperidol in reducing positive symptoms and 300 mg/day was superior to placebo and comparable with haloperidol for negative symptoms. 

Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K. A randomized, double-bhnd, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005 66 111-21. 

Other atypical antipsychotics commonly prescribed for treatment of autism include olanzapine, quetiapine, ziprasidone, and clozapine (Oswald and Sonenklar, 2007). Placebo-controlled trials of these agents in ASD populations have not been reported, with the exception of a small pilot study of olanzapine in which three of six children treated with olanzepine were rated as responders, compared to one of five in the placebo group (Hollander et al., 2006b). Open-label studies (reviewed by... 

---